Fluidoro, which contains the active substance prasugrel, belongs to a group of medicines called platelet antiplatelet agents.
Fluidoro inhibits the accumulation of platelets and thus reduces the risk of blood clots.


Fluidoro co-administered with acetylsalicylic acid (ASA) has been shown to prevent atherothrombotic events in adult patients with acute coronary syndrome (eg unstable angina, non-ST-segment elevation myocardial infarction [UA/NSTEMI] or myocardial infarction) of ST [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI).

Subject to medical prescription.

Concentration and pharmaceutical form: 10 mg film-coated tablets